10 Biotech Stocks With The Biggest Upside
In this article, we discuss the 10 biotech stocks with the biggest upside. If you want to read about some more biotech stocks with the biggest upside, go directly to 5 Biotech Stocks With The Biggest ...
- Supported exchanges /
- NASDAQ /
- VRAX.NASDAQ
Virax Biolabs Group Limited Ordinary Shares (VRAX NASDAQ) stock market data APIs
$3.51
0.67(23.6%)
as of September 16, 2024
Price chart is built with Anychart
Virax Biolabs Group Limited, a biotechnology company, distributes, markets, and sells diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
Virax Biolabs Group Limited Ordinary Shares Financial Data Overview
| 2.84 | |
| 3.51 | |
| - | |
| 3.5494 | |
| 2.675 | |
| 0.6-7.63 | |
| 11 246 K | |
| 4 342 K | |
| 156 K | |
| -0.03 | |
| 2.051 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'VRAX',
Type:
'Common Stock',
Name:
'Virax Biolabs Group Limited Ordinary Shares',
Exchange:
'NASDAQ',
CurrencyCode:
'USD',
CurrencyName:
'US Dollar',
CurrencySymbol:
'$',
CountryName:
'USA',
CountryISO:
'US',
OpenFigi:
'BBG0166WT3L7',
ISIN:
NULL,
CUSIP:
NULL,
CIK:
'1885827',
EmployerIdNumber:
NULL,
FiscalYearEnd:
'March',
IPODate:
'2022-07-21',
InternationalDomestic:
NULL,
Sector:
'Healthcare',
Industry:
'Biotechnology',
HomeCategory:
NULL,
IsDelisted:
false,
}
Virax Biolabs Group Limited Ordinary Shares Fundamental Data is available in our Financial Data APIs
- Net Revenue 156 K
- EBITDA -6 051 248
- Earnings Per Share -3.36
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Virax Biolabs Group Limited Ordinary Shares Earnings via APIs
- Latest Release 2022-07-21
- EPS/Forecast 0
Get Virax Biolabs Group Limited Ordinary Shares End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Virax Biolabs Group Limited Ordinary Shares latest news via APIs
Weekly tally of COVID cases and deaths continues to fall; Moderna lowers vaccine-sales outlook by as much as $3 billion
The global tally of COVID cases fell 17% in the week through Oct. 30 from the previous week, while the death toll fell 5%, the World Health Organization said in its weekly update on the virus. Continue reading
- CORONAVIRUS UPDATE
- OMICRON VARIANT
- PHOTO ILLUSTRATION
- WORLD HEALTH ORGANIZATION
- XBB
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
